Apollomics (NASDAQ:APLM) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Apollomics (NASDAQ:APLM) to a hold rating in a report published on Saturday.

Separately, Weiss Ratings upgraded Apollomics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, August 17th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Apollomics Price Performance

Shares of NASDAQ:APLM opened at $23.73 on Friday. The firm has a fifty day simple moving average of $19.23 and a two-hundred day simple moving average of $17.46. Apollomics has a 52 week low of $3.66 and a 52 week high of $42.12.

Insider Transactions at Apollomics

In other news, CFO Peter Kuan-How Lin acquired 26,667 shares of Apollomics stock in a transaction that occurred on Friday, August 14th. The shares were bought at an average cost of $15.00 per share, with a total value of $400,005.00. Following the transaction, the chief financial officer directly owned 48,979 shares of the company’s stock, valued at $734,685. This trade represents a 119.52% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, COO Yi-Kuei Chen acquired 20,000 shares of the firm’s stock in a transaction on Friday, August 14th. The stock was purchased at an average cost of $15.00 per share, with a total value of $300,000.00. Following the purchase, the chief operating officer owned 121,248 shares of the company’s stock, valued at $1,818,720. The trade was a 19.75% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders bought 583,334 shares of company stock worth $8,250,510.

Institutional Investors Weigh In On Apollomics

An institutional investor recently bought a new stake in Apollomics stock. Kestra Advisory Services LLC purchased a new position in shares of Apollomics Inc. (NASDAQ:APLM) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 4,380 shares of the company’s stock, valued at approximately $82,000. Kestra Advisory Services LLC owned about 0.40% of Apollomics as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 19.13% of the company’s stock.

Apollomics Company Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.

Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.